2.42
price down icon2.42%   -0.06
after-market After Hours: 2.39 -0.03 -1.24%
loading
Neuraxis Inc stock is traded at $2.42, with a volume of 30,126. It is down -2.42% in the last 24 hours and down -11.36% over the past month. NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.48
Open:
$2.48
24h Volume:
30,126
Relative Volume:
0.02
Market Cap:
$23.72M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.0002
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+2.11%
1M Performance:
-11.36%
6M Performance:
+2.98%
1Y Performance:
-12.95%
1-Day Range:
Value
$2.42
$2.50
1-Week Range:
Value
$2.33
$2.65
52-Week Range:
Value
$1.33
$6.20

Neuraxis Inc Stock (NRXS) Company Profile

Name
Name
Neuraxis Inc
Name
Phone
(812) 689-0791
Name
Address
11550 North Meridian Street, Suite 325, Carmel
Name
Employee
17
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
NRXS's Discussions on Twitter

Compare NRXS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NRXS
Neuraxis Inc
2.42 23.72M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Neuraxis Inc Stock (NRXS) Latest News

pulisher
Jun 17, 2025

Neuraxis announces new medical policy with two health insurers - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

NeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal Pain - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

NeurAxis (NASDAQ:NRXS) Now Covered by Analysts at Craig Hallum - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

Neuraxis (NRXS) Initiated with Buy Rating by Craig-Hallum | NRXS Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Craig-Hallum initiates NeurAxis stock with buy rating on pediatric device - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

Craig-Hallum bullish on Neuraxis, initiates with a Buy - TipRanks

Jun 16, 2025
pulisher
Jun 10, 2025

Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain in Ibs - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

NeurAxis (NRXS) Gains Momentum with Key Guideline Inclusion | NR - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Neuraxis secures key academic society guidelines recommendation for FAP - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

NeurAxis Achieves Critical Milestone; Secures Key Academic - GlobeNewswire

Jun 10, 2025
pulisher
Jun 10, 2025

Major Medical Guidelines Back NeurAxis $3B IBS Treatment for Children, Only FDA-Cleared Option - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

47,094 Shares in NeurAxis, Inc. (NASDAQ:NRXS) Bought by Citadel Advisors LLC - Defense World

Jun 10, 2025
pulisher
Jun 04, 2025

NeurAxis, Inc. Approves Key Proposals at Annual Meeting - TipRanks

Jun 04, 2025
pulisher
May 28, 2025

NeurAxis, Inc. Releases Investor Presentation - TipRanks

May 28, 2025
pulisher
May 27, 2025

NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times

May 27, 2025
pulisher
May 23, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

May 23, 2025
pulisher
May 22, 2025

NeurAxis Closes $5 Million Direct Offering - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq

May 22, 2025
pulisher
May 22, 2025

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

NeurAxis announces USD 5M registered direct offering - Medical Buyer

May 22, 2025
pulisher
May 22, 2025

NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks

May 22, 2025
pulisher
May 22, 2025

Form 424B5 Neuraxis, INC - StreetInsider

May 22, 2025
pulisher
May 22, 2025

SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow

May 22, 2025
pulisher
May 21, 2025

Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks

May 21, 2025
pulisher
May 21, 2025

Neuraxis settles lawsuit with $750,000 agreement - Investing.com

May 21, 2025
pulisher
May 21, 2025

NeurAxis slides 21%, raises $5M via stock - MSN

May 21, 2025
pulisher
May 21, 2025

Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize

May 21, 2025
pulisher
May 21, 2025

NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq

May 21, 2025
pulisher
May 21, 2025

NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus

May 21, 2025
pulisher
May 21, 2025

NeurAxis Launches $5 Million Direct Offering - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks

May 21, 2025
pulisher
May 21, 2025

NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times

May 21, 2025
pulisher
May 20, 2025

NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit

May 20, 2025
pulisher
May 20, 2025

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga

May 20, 2025
pulisher
May 20, 2025

Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com

May 20, 2025
pulisher
May 20, 2025

NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph

May 20, 2025
pulisher
May 20, 2025

Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent

May 20, 2025
pulisher
May 20, 2025

Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga

May 20, 2025
pulisher
May 20, 2025

NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com

May 20, 2025
pulisher
May 20, 2025

NeurAxis, Inc. Receives First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia and Associated Nausea Symptoms - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews

May 20, 2025
pulisher
May 20, 2025

NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus

May 20, 2025

Neuraxis Inc Stock (NRXS) Financials Data

There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
Cap:     |  Volume (24h):